Psychedelic drugs should be legally reclassified as they may benefit patients, psychiatrist says

May 26, 2015

Legal restrictions imposed on medical use of psychedelic drugs, such as LSD and psilocybin (the compound found in 'magic' mushrooms), are making trials almost impossible and authorities should 'downgrade their unnecessarily restrictive class A, schedule 1 classification,' writes a psychiatrist in The BMJ this week.

James Rucker, a psychiatrist and honorary lecturer at the Institute of Psychiatry, Psychology and Neuroscience, King's College London, describes how these drugs "were extensively used and researched in clinical psychiatry" before their prohibition in 1967.

He explains that many trials of psychedelics published before prohibition, in the 1950s and 1960s, suggested "beneficial change in many psychiatric disorders".

However, research ended after 1967. In the UK psychedelic drugs were legally classified as schedule 1 class A drugs - that is, as having "no accepted medical use and the greatest potential for harm, despite the research evidence to the contrary," he writes.

Rucker points out that psychedelics remain more legally restricted than heroin and cocaine. "But no evidence indicates that are habit forming; little evidence indicates that they are harmful in controlled settings; and much historical evidence shows that they could have use in common ."

In fact, recent studies indicate that psychedelics have "clinical efficacy in anxiety associated with advanced cancer, , tobacco and alcohol addiction, and cluster headaches," he writes.

And he explains that, at present, larger clinical studies on psychedelics are made "almost impossible by the practical, financial and bureaucratic obstacles" imposed by their schedule 1 classification. Currently, only one manufacturer in the world produces psilocybin for trial purposes, he says, at a "prohibitive" cost of £100,000 for 1 g (50 doses).

In the UK, to hold a schedule 1 drug, institutions require a license, which costs about £5,000, he adds. Only four hospitals currently hold such licenses, which come with regular police or home office inspections and onerous rules on storage and transport.

This, he argues, "means that clinical research using psychedelics costs 5-10 times that of research into less restricted (but more harmful) drugs such as heroin."

As a result, "almost all grant funders are uncomfortable funding research into psychedelics," writes Rucker, while prohibition as a condition of UN membership is "arguably causing more harm than it prevents."

He concludes that psychedelics are neither harmful nor addictive compared with other controlled substances, and he calls on the UK Advisory Council on the Misuse of Drugs and the 2016 UN General Assembly Special Session on Drugs, "to recommend that psychedelics be reclassified as schedule 2 compounds to enable a comprehensive, evidence based assessment of their therapeutic potential."

Explore further: No link between psychedelics and mental health problems

More information: Personal View: Psychedelic drugs should be legally reclassified so researchers can investigate their therapeutic potential, The BMJ, www.bmj.com/cgi/doi/10.1136/bmj.h2746

Related Stories

No link between psychedelics and mental health problems

March 5, 2015
The use of psychedelics, such as LSD and magic mushrooms, does not increase a person's risk of developing mental health problems, according to an analysis of information from more than 135,000 randomly chosen people, including ...

Use of psychedelic drugs remains prevalent in the US

April 23, 2013
An article published in F1000Research, and approved for indexing in PubMed and other major bibliographical databases, estimates that there were approximately 32 million users of psychedelic drugs in the United States in 2010.

LSD, other psychedelics not linked with mental health problems in new study

August 19, 2013
The use of LSD, magic mushrooms, or peyote does not increase a person's risk of developing mental health problems, according to an analysis of information from more than 130,000 randomly chosen people, including 22,000 people ...

Psychedelic drug use could reduce psychological distress, suicidal thinking

March 9, 2015
A history of psychedelic drug use is associated with less psychological distress and fewer suicidal thoughts, planning and attempts, according to new research from Johns Hopkins and the University of Alabama at Birmingham.

More research needed on benefits of psychedelic drugs

October 9, 2014
A University of Adelaide philosophy scholar is calling for more research into the therapeutic benefits of psychedelic drugs, with early studies suggesting these substances can provide lasting psychological benefits.

Classic psychedelic use found to be protective with regard to psychological distress and suicidality, study finds

January 21, 2015
Classic psychedelics, such as LSD, psilocybin mushrooms and mescaline, previously have been shown to occasion lasting improvements in mental health. But researchers led by University of Alabama at Birmingham School of Public ...

Recommended for you

Probing how Americans think about mental life

October 20, 2017
When Stanford researchers asked people to think about the sensations and emotions of inanimate or non-human entities, they got a glimpse into how those people think about mental life.

Itsy bitsy spider: Fear of spiders and snakes is deeply embedded in us

October 19, 2017
Snakes and spiders evoke fear and disgust in many people, even in developed countries where hardly anybody comes into contact with them. Until now, there has been debate about whether this aversion is innate or learnt. Scientists ...

Dutch courage—Alcohol improves foreign language skills

October 18, 2017
A new study published in the Journal of Psychopharmacology, conducted by researchers from the University of Liverpool, Maastricht University and King's College London, shows that bilingual speakers' ability to speak a second ...

Inflamed support cells appear to contribute to some kinds of autism

October 18, 2017
Modeling the interplay between neurons and astrocytes derived from children with Autism Spectrum Disorder (ASD), researchers at University of California San Diego School of Medicine, with colleagues in Brazil, say innate ...

Study suggests psychedelic drugs could reduce criminal behavior

October 18, 2017
Classic psychedelics such as psilocybin (often called magic mushrooms), LSD and mescaline (found in peyote) are associated with a decreased likelihood of antisocial criminal behavior, according to new research from investigators ...

Taking probiotics may reduce postnatal depression

October 18, 2017
Researchers from the University of Auckland and Otago have found evidence that a probiotic given in pregnancy can help prevent or treat symptoms of postnatal depression and anxiety.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.